Larimar Therapeutics: Funding, Investors & Team (Sep 2026)
Larimar Therapeutics, Inc. is a biotechnology company in the clinical stage that is dedicated to creating therapies for rare diseases. Their main focus is on developing treatments for complex rare diseases, with their lead compound, CTI-1601, currently in Phase 1 clinical trials for Friedreich’s ataxia. Additionally, Larimar intends to utilize their intracellular delivery platform to create fusion proteins to target other rare diseases that involve deficiencies in intracellular bioactive compounds.
Larimar Therapeutics has raised $403M across 4 funding rounds on record, the most recent an undisclosed round of $100M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Larimar Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Larimar Therapeutics Funding Rounds
Larimar Therapeutics raised $70.0M in a Post-IPO Equity announced in Sep 2022.
1.4 years later, an undisclosed round of $173M was announced in Feb 2024.
1.4 years later, an undisclosed round of $60.0M was announced in Jul 2025.
7 months later, an undisclosed round of $100M was announced in Feb 2026.
Larimar Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Larimar Therapeutics Funding Compared to Other Biotechnology Startups
Larimar Therapeutics' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Larimar Therapeutics in Biotechnology and Bala Cynwyd
Companies Similar to Larimar Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Larimar Therapeutics Funding FAQs
What does Larimar Therapeutics do?
Larimar Therapeutics, Inc. is a biotechnology company in the clinical stage that is dedicated to creating therapies for rare diseases. Their main focus is on developing treatments for complex rare diseases, with their lead compound, CTI-1601, currently in Phase 1 clinical trials for Friedreich’s ataxia. Additionally, Larimar intends to utilize their intracellular delivery platform to create fusion proteins to target other rare diseases that involve deficiencies in intracellular bioactive compounds.
How much funding has Larimar Therapeutics raised?
Larimar Therapeutics has raised $403M across 4 rounds on record. The most recent is an undisclosed round of $100M announced in Feb 2026.
When did Larimar Therapeutics last raise funding?
Larimar Therapeutics' most recent funding round on record is an undisclosed round of $100M, announced in Feb 2026.
Who founded Larimar Therapeutics?
FundedIQ lists Maria Rupnick (Founder) at Larimar Therapeutics.
Where is Larimar Therapeutics headquartered?
Larimar Therapeutics is based in Bala Cynwyd, Pennsylvania, United States.
How many employees does Larimar Therapeutics have?
Larimar Therapeutics is in the 51-100 employee band.
How does Larimar Therapeutics' funding compare to other Biotechnology startups?
Larimar Therapeutics' latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Larimar Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Larimar Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.